23 Matching Annotations
  1. Dec 2024
    1. A period of emigration by Russian Jews — many to America — began in earnest.

      How many Russian Jews emigrated to the USA in this decade?

      Cite your source(s).

  2. Mar 2024
  3. Feb 2024
    1. The Second Triumvirate was an extraordinary commission and magistracy created for Mark Antony, Lepidus, and Octavian to give them practically absolute power. It was formally constituted by law on[1] 27 November 43 BC with a term of five years; it was renewed in 37 BC for another five years before expiring in 32 BC.
  4. Mar 2023
  5. Oct 2022
  6. Sep 2022
  7. Mar 2021
    1. Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).

      AssayResult: 4

      AssayResultAssertion: Indeterminate

      StandardErrorMean: 0.1

    2. A total of 84 PALB2 patient-derived missense variants reported in ClinVar, COSMIC, and the PALB2 LOVD database were selected

      HGVS: NM_024675.3:c.2840T>C p.(Leu947Ser)

    1. SUPPLEMENTARY DATA

      AssayResult: 109.4

      AssayResultAssertion: Not reported

      PValue: > 0.9999

      Comment: Exact values reported in Table S3.

    2. To this end, 44 missense variants found in breast cancer patients were identified in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar) and/or selected by literature curation based on their frequency of description or amino acid substitution position in the protein (Supplemental Table S1).

      HGVS: NM_024675.3:c.949A>C p.(Thr317Pro)

    1. Source Data

      AssayResult: 52.23

      AssayResultAssertion: Not reported

      ReplicateCount: 2

      StandardErrorMean: 6.33

      Comment: Exact values reported in “Source Data” file. Discrepancy in “Source Data” file: protein reported as I1037R.

    2. Source Data

      AssayResult: 38.85

      AssayResultAssertion: Abnormal

      ReplicateCount: 2

      StandardDeviation: 3.05

      StandardErrorMean: 2.15

      Comment: Exact values reported in “Source Data” file.

    3. We, therefore, analyzed the effect of 48 PALB2 VUS (Fig. 2a, blue) and one synthetic missense variant (p.A1025R) (Fig. 2a, purple)29 on PALB2 function in HR.

      HGVS: NM_024675.3:c.3110T>C p.(I1037T)

    1. Most Suspected Brugada Syndrome Variants Had (Partial) Loss of Function

      AssayResult: 102.4

      AssayResultAssertion: Normal

      ReplicateCount: 39

      StandardErrorMean: 15.5

      Comment: This variant had normal function (75-125% of wildtype peak current, <1% late current, no large perturbations to other parameters). These in vitro features are consistent with non-disease causing variants. (Personal communication: A. Glazer)

    2. we selected 73 previously unstudied variants: 63 suspected Brugada syndrome variants and 10 suspected benign variants

      HGVS: NM_198056.2:c.3841G>T p.(Val1281Phe)

  8. Feb 2021
    1. Supplemental material

      AssayResult: 84

      AssayResultAssertion: Normal

      Comment: See Table S2 for details

    2. Supplemental material

      AssayResult: 2.8

      AssayResultAssertion: Abnormal

      Comment: See Table S2 for details

    3. We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.

      HGVS: NM_000546.5:c.818G>A p.(Arg273His)

  9. Dec 2018
    1. And I know that the record which I make is true. And I make it with mine own hand and I make it according to my knowledge.

      In the first paragraph there is an evocation of the triad of First Principles: Mythos, Typos, Logos (GOD, Place, Word) The Mythic moves and opens up spaces. From that spatial existence known by/as Persons and Places come Things - works/words, art/artifacts, etc. Myths open spaces and rational accounts limit them. These are two parts of one eternal process. Mythos creates space through its mysterious movements. Then within the spatial existence opened by Mythos we have a spatial/special relationship between Peope & Place which always begins to generate Names and other Words. From there the Spirit continues to flow through linguistic channels (Logos) and finally deposited back into the realm of Myth to begin again. [If at any point in this process there is a failure to complete and continue the cycle then what comes about is "vain imaginings" as opposed to the reimagining encouraged on this site. This will be a major theme throughout the BOM.]

      Limitation - One man's account, one man's knowledge. The content itself is a product of the quality of experience and great knowledge accumulated through the person of Nephi (who is likely a higher dimensional type for millions of others who share to some degree in the experience of "favor" and "goodness" on any and all planes). The accuracy of recording relies on the "Learning of the Jews" (Scientific Judgements and Measurements of Truth) and the "Language of the Egyptians" (Science of Expression of Truth through Active Arts).<br> Compare Alma 32:26-43